Total Funding
73
13
Total FundingVenture - Series Unknown raised
Growth Score 73 in past quarter
-6 pts
Heat Score 13 in past quarter
-15 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
2934139
NephRx develops therapeutic products for acute kidney failure, renal disorders, and diseases of the gastrointestinal tract.
- James T. VanderLugt: Chief Medical Officer
- James Koziarz: President & CEO
About the Company
NephRx Corporation, a biotechnology company, engages in the discovery and development of therapeutic products for the treatment of acute kidney failure, renal disorders, and diseases of the gastrointestinal tract. It provides NX001, which is useful for the treatment of delayed graft function in kidney transplant patients; and NX002, a peptide that
is derived from the naturally occurring growth factor AMP-18. The company was incorporated in 1995 and is based in Kalamazoo, Michigan.
